vision changes on tirzepatide Why Your GLP-1 Medications (And What It Means) | Dr. Dan | Obesity Expert Our vitreoretinal surgeon explains what

The metabolic impact of dual receptor activation appears to produce greater weight loss in clinical trials compared to GLP-1-only medications at comparable doses

This dual mechanism is why tirzepatide consistently produces greater weight loss in clinical trials

"And remember these are associations, not causations, so it's not to say that GLP-1 use causes NAION or worsening retinopathy, but their use is associated with these conditions." "From an ophthalmologic standpoint, these findings underscore the importance of baseline and follow-up eye examinations for patients starting GLP-1 therapy, especially those with pre-existing retinal or optic nerve risk factors." The expert added that while the benefits of GLP-1 medications in reducing cardiovascular and metabolic risks are "substantial," patients should be counseled on potential visual side effects, and "any sudden visual symptoms should prompt immediate ophthalmic referral." For more Health articles, visit www.foxnews.com/health Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital

Discuss alternatives with your endocrinologist before making any changes

They happen to almost everyone on GLP-1 receptor agonists, and they happen regardless of how disciplined the protocol is